The European Medicines Agency approval of 5-aminolaevulinic acid (Ameluz) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use

MLA

Tzogani, Kyriaki, et al. “The European Medicines Agency Approval of 5-Aminolaevulinic Acid (Ameluz) for the Treatment of Actinic Keratosis of Mild to Moderate Intensity on the Face and Scalp: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.” Journal of Dermatological Treatment, vol. 25, no. 5, Oct. 2014, pp. 371–74. EBSCOhost, https://doi.org/10.3109/09546634.2013.789474.

APA

Tzogani, K., Straube, M., Hoppe, U., Kiely, P., O’Dea, G., Enzmann, H., Salmon, P., Salmonson, T., & Pignatti, F. (2014). The European Medicines Agency approval of 5-aminolaevulinic acid (Ameluz) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Journal of Dermatological Treatment, 25(5), 371–374. https://doi.org/10.3109/09546634.2013.789474

Chicago

Tzogani, Kyriaki, Myrjam Straube, Ute Hoppe, Peter Kiely, Geraldine O’Dea, Harald Enzmann, Patrick Salmon, Tomas Salmonson, and Francesco Pignatti. 2014. “The European Medicines Agency Approval of 5-Aminolaevulinic Acid (Ameluz) for the Treatment of Actinic Keratosis of Mild to Moderate Intensity on the Face and Scalp: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.” Journal of Dermatological Treatment 25 (5): 371–74. doi:10.3109/09546634.2013.789474.